ClinicalTrials.gg
CompletedNCT07773909Updated Aug 21, 2026

Venetoclax With Hypomethylating Agents in Newly Diagnosed AML Unfit for Intensive Chemotherapy

A Phase 4 interventional study of Venetoclax and Azacitidine in Acute Myeloid Leukemia, sponsored by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. Completed at 1 site in Bangladesh. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 2 months after the study started (first participant enrolled Jun 2022, registered Aug 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 202 studies testing venetoclax in Leukemia, Myeloid, Acute — 116 open to participants now, 144 under way, 21 of them phase 3. venetoclax · Leukemia, Myeloid, Acute.

Enrollment
162nd of 202
24 · median 57
Started
2022
with 30 others
Phase 4
5 of 202
3 open now
Registered
199th of 202
by date

Among the 202 studies testing venetoclax in Leukemia, Myeloid, Acute, this one is the 162nd largest by enrollment, is one of 31 that started in 2022, is one of 5 in phase 4, and was the 199th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

116 of the 202 studies testing venetoclax in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

111 more — sign in →

By country, each count listing its studies:

All 116 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 202 studies testing venetoclax in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This single-arm interventional study evaluated the short-term outcome of one 28-day cycle of venetoclax combined with a hypomethylating agent (azacitidine or decitabine) in adults with newly diagnosed acute myeloid leukemia who could not receive intensive induction chemotherapy. Twenty-four patients were enrolled at the Department of Haematology, Dhaka Medical College Hospital, Dhaka, Bangladesh. In addition to older and comorbid patients, the cohort included younger patients for whom intensive chemotherapy was financially inaccessible - a population under-represented in existing trial and registry data. The primary endpoint was the composite remission rate (complete remission plus complete remission with incomplete haematologic recovery) assessed by bone marrow examination on Day 28. Secondary endpoints included change in complete blood count parameters, treatment-emergent adverse events, and 28-day mortality.

Read the detailed description

Background and Rationale

Acute myeloid leukemia (AML) predominantly affects older adults, who often cannot tolerate intensive induction chemotherapy due to comorbidity or poor performance status. In low- and middle-income countries like Bangladesh, a secondary population-younger, medically fit patients-is also unable to receive intensive therapy due to prohibitive costs. While hypomethylating agents (HMAs) combined with venetoclax represent a standard lower-intensity approach, real-world data on this regimen are lacking in Bangladesh and sparse for financially constrained younger cohorts. This study evaluates the short-term outcomes of a single cycle of venetoclax plus an HMA in both groups at a public tertiary care hospital.

Intervention Details \& Dosing Nuances

Participants receive one 28-day cycle consisting of either IV azacitidine (75 mg/m² daily on Days 1-7) or IV decitabine (20 mg/m² daily on Days 1-5), based on physician discretion. Oral venetoclax is administered at 100 mg on Day 1, 200 mg on Day 2, and maintained at 100 mg daily from Day 3 to Day 28. The venetoclax dose is intentionally capped at 100 mg daily (instead of standard higher dosing) because all participants receive concomitant oral voriconazole (200 mg twice daily, Days 3-28) for antifungal prophylaxis, a strong CYP3A4 inhibitor requiring mandatory venetoclax dose reduction. Tumour lysis syndrome prophylaxis and standard supportive care (transfusions, antimicrobials) are provided per institutional protocols.

03

Conditions studied

  • Acute Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed acute myeloid leukemia
  • Age 18 years or older
  • Deemed ineligible for intensive chemotherapy by the treating physician based on age (≥60 years), performance status or comorbidity, financial constraints, or patient unwillingness to receive intensive chemotherapy
  • Written

Exclusion criteria

Exclusion Criteria:

  • Acute promyelocytic leukemia
  • Previous treatment with a hypomethylating agent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Venetoclax + Hypomethylating Agent

    Single arm. All participants received one 28-day cycle of venetoclax combined with either azacitidine or decitabine at investigator discretion, with antifungal prophylaxis.

    Drug: Venetoclax · Drug: Azacitidine · Drug: Decitabine · Drug: Voriconazole

Interventions

  • Oral venetoclax 100 mg on Day 1, 200 mg on Day 2, then 100 mg daily Days 3-28. Dose maintained at 100 mg from Day 3 because of concomitant strong CYP3A4 inhibition by voriconazole.

  • 75 mg/m² intravenously, Days 1-7 of the 28-day cycle.

  • 20 mg/m² intravenously, Days 1-5 of the 28-day cycle.

  • 200 mg orally twice daily, Days 3-28, as antifungal prophylaxis.

06

What researchers measure

Primary outcomes

  1. Composite remission rate (CR + CRi) after one cycle

    Proportion of participants achieving complete remission (bone marrow blasts \<5%, absence of circulating blasts and Auer rods, no extramedullary disease, ANC ≥1000/µL, platelets ≥100,000/µL) or CR with incomplete haematologic recovery (all CR criteria except residual neutropenia or thrombocytopenia), assessed on Day 28 bone marrow examination.

    Time frame: Day 28 (end of cycle 1)

Secondary outcomes

  1. Change in total WBC count from baseline

    Time frame: Baseline and Day 28

  2. Change in absolute/differential neutrophil count from baseline

    Time frame: Baseline and Day 28

  3. Change in haemoglobin concentration from baseline

    Time frame: Baseline and Day 28

  4. Change in platelet count from baseline

    Time frame: Baseline and Day 28

  5. Change in peripheral blood blast percentage from baseline

    Time frame: Baseline and Day 28

  6. Change in bone marrow blast percentage from baseline

    Time frame: Baseline and Day 28

  7. Number of participants with treatment-emergent adverse events

    Time frame: Day 1 to Day 28

  8. All-cause mortality

    Time frame: Day 1 to Day 28

07

Study locations

1 site
  • Dhaka Medical College Hospital
    Dhaka, 1000, Bangladesh
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Mar 2023, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2026
First posted
Aug 19, 2026
StartActual
Jun 1, 2022
Primary completionActual
Mar 1, 2023
CompletionActual
Mar 1, 2023
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07773909
Responsible party
Talha Islam Zinan (Doctor, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh) — Principal investigator
First posted
Aug 19, 2026
Start date
Jun 1, 2022
Primary completion
Mar 1, 2023
Completion
Mar 1, 2023
Last update
Aug 21, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion